(UPDATED FEBRUARY 8) Last month’s granting of an Amgen permanent injunction motion in its cholesterol drug patent dispute with Sanofi and Regeneron would “give another arrow in the quiver” of those seeking permanent injunctions in similar cases, if it is upheld on appeal
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck
Penelope Aspinall, of IP wellbeing charity Jonathan’s Voice, explains why managers should take a three-tiered approach to looking after workers’ mental health